U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula 2C18H24O2.H2O
Molecular Weight 562.7792
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ESTRADIOL HEMIHYDRATE

SMILES

O.[H][C@@]12CC[C@H](O)[C@@]1(C)CC[C@]3([H])C4=C(CC[C@@]23[H])C=C(O)C=C4.[H][C@@]56CC[C@H](O)[C@@]5(C)CC[C@]7([H])C8=C(CC[C@@]67[H])C=C(O)C=C8

InChI

InChIKey=ZVVGLAMWAQMPDR-WVEWYJOQSA-N
InChI=1S/2C18H24O2.H2O/c2*1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20;/h2*3,5,10,14-17,19-20H,2,4,6-9H2,1H3;1H2/t2*14-,15-,16+,17+,18+;/m11./s1

HIDE SMILES / InChI

Molecular Formula C18H24O2
Molecular Weight 272.382
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 5 / 5
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020375s027lbl.pdf

Estradiol an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. In humans, it is produced primarily by the cyclic ovaries and the placenta. It is also produced by the adipose tissue of men and postmenopausal women. The 17-alpha-isomer of estradiol binds weakly to estrogen receptors (receptors, estrogen) and exhibits little estrogenic activity in estrogen-responsive tissues. Estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estradiol is used for the treatment of urogenital symptoms associated with post-menopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). Estradiol is marketed under the brand name Climara (among others), indicated for: the treatment of moderate to severe vasomotor symptoms due to menopause, treatment of symptoms of vulvar and vaginal atrophy due to menopause, treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure and prevention of postmenopausal osteoporosis.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: P08842
Gene ID: 412.0
Gene Symbol: STS
Target Organism: Homo sapiens (Human)
0.0084 nM [EC50]
1.4 nM [EC50]
19.1 nM [IC50]
0.13 nM [Ki]
0.09 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CLIMARA

Approved Use

Climara is an estrogen indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause •Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure •Prevention of Postmenopausal Osteoporosis

Launch Date

1974
Preventing
CLIMARA

Approved Use

Climara is an estrogen indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause •Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure •Prevention of Postmenopausal Osteoporosis

Launch Date

1974
Primary
CLIMARA

Approved Use

Climara is an estrogen indicated for: •Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause •Treatment of Moderate to Severe Symptoms of Vulvar and Vaginal Atrophy due to Menopause •Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure •Prevention of Postmenopausal Osteoporosis

Launch Date

1974
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
14.7 pg/mL
0.25 mg 1 times / day steady-state, topical
dose: 0.25 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
ESTRADIOL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
92 pg/mL
0.05 mg 1 times / day multiple, topical
dose: 0.05 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
ESTRADIOL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
236 pg × h/mL
0.25 mg 1 times / day steady-state, topical
dose: 0.25 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
ESTRADIOL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
10 h
0.25 mg 1 times / day steady-state, topical
dose: 0.25 mg
route of administration: Topical
experiment type: STEADY-STATE
co-administered:
ESTRADIOL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
1.75 h
0.05 mg 1 times / day multiple, topical
dose: 0.05 mg
route of administration: Topical
experiment type: MULTIPLE
co-administered:
ESTRADIOL plasma
Homo sapiens
population: UNKNOWN
age: ADULT
sex: FEMALE
food status: UNKNOWN
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
minor
minor
minor
minor
minor
minor
no
no
no
no
no
no
no
no
no
yes [Km 7 uM]
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Estradiol prevents and testosterone promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression.
1999
Comparison of the pharmacokinetics of 17 beta-estradiol after a single 4-day application of Oesclim 50, Oesclim 100, and Vivelle 0.05 (Menorest 50) transdermal delivery systems.
1999 Aug
Inhibitory effect of natural and environmental estrogens on thymic hormone production in thymus epithelial cell culture.
1999 Dec
Estrogen-induced pituitary tumor development in the ACI rat not inhibited by dietary energy restriction.
1999 Dec
Low-dose bioactivity of xenoestrogens in animals: fetal exposure to low doses of methoxychlor and other xenoestrogens increases adult prostate size in mice.
1999 Jan-Mar
Estrogenic potential of certain pyrethroid compounds in the MCF-7 human breast carcinoma cell line.
1999 Mar
Effects of environmental estrogens on tumor necrosis factor alpha-mediated apoptosis in MCF-7 cells.
1999 Nov
Estrogen directly respresses gonadotropin-releasing hormone (GnRH) gene expression in estrogen receptor-alpha (ERalpha)- and ERbeta-expressing GT1-7 GnRH neurons.
1999 Nov
Perinatal exposure to estrogenic compounds and the subsequent effects on the prostate of the adult rat: evaluation of inflammation in the ventral and lateral lobes.
1999 Nov-Dec
Transcriptional activation of c-fos protooncogene by 17beta-estradiol: mechanism of aryl hydrocarbon receptor-mediated inhibition.
1999 Sep
Acute activation of Maxi-K channels (hSlo) by estradiol binding to the beta subunit.
1999 Sep 17
Estradiol and pesticide methoxychlor do not exhibit additivity or synergism in the reproductive tract of adult ovariectomized mice.
2000 Jul 28
Crosstalk between estrogen receptor alpha and the aryl hydrocarbon receptor in breast cancer cells involves unidirectional activation of proteasomes.
2000 Jul 28
Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription.
2000 Mar
Changes in serum and tissue zinc levels in sex hormone-induced prostatic carcinogenesis in the noble rat.
2000 Nov-Dec
Effects of arsenite on estrogen receptor-alpha expression and activity in MCF-7 breast cancer cells.
2000 Oct
Repression of chick multidrug resistance-associated protein 1 (chMRP1) gene expression by estrogen.
2000 Oct 31
Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer.
2001 Apr 6
Vitellogenin-induced pathology in male summer flounder (Paralichthys dentatus).
2001 Feb
Female steroid hormones modulate receptors for nerve growth factor in rat dorsal root ganglia.
2001 Jan
Increased expression of a novel heat shock protein transcript in the mouse uterus during decidualization and in response to progesterone.
2001 Jan
Follicle selection in cattle: role of luteinizing hormone.
2001 Jan
Metabolism of estradiol, ethynylestradiol, and moxestrol in rat uterus, vagina, and aorta: influence of sex steroid treatment.
2001 Jan
Oestrogen-induced changes in the synaptology of the monkey (Cercopithecus aethiops) arcuate nucleus during gonadotropin feedback.
2001 Jan
Heat-shock factor-1, steroid hormones, and regulation of heat-shock protein expression in the heart.
2001 Jan
Evaluation of an EIA method for measuring serum levels of the estrogen metabolite 2-hydroxyestrone in adults.
2001 Jan
Effects of heterocyclic amines with mammary gland carcinogenic potential on estrogenic response of uterus in ovariectomized rats.
2001 Jan 10
Hormone binding by protein disulfide isomerase, a high capacity hormone reservoir of the endoplasmic reticulum.
2001 Jan 5
Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus.
2007 Mar 10
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Estradiol benzoate is not approved by the FDA for use in humans in the United States.
Unknown
Route of Administration: Unknown
Estradiol-3-sulfate (E2SO4) infused intracerebroventricularly (icv) significantly increased plasma adrenocorticotropic hormone (ACTH) and cortisol concentrations. All minipumps in the treated fetuses were filled with E2SO4 in the vehicle (water) and minipumps in the control fetuses were filled with vehicle only. These minipumps deliver a constant infusion of 5 μL/h; the concentration of E2SO4 in infusates was therefore 8.33 μg/μL. It was concluded, that E2SO4 had complex actions on the fetal brain, which might involve deconjugation by steroid sulfatase. But that the net result of direct E2SO4 icv infusion was more complex than could be accounted for by infusion of E2 alone.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:57:12 GMT 2023
Edited
by admin
on Fri Dec 15 15:57:12 GMT 2023
Record UNII
CXY7B3Q98Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ESTRADIOL HEMIHYDRATE
EP   MI   ORANGE BOOK   WHO-DD  
Common Name English
Estradiol hemihydrate [WHO-DD]
Common Name English
ESTRADIOL HEMIHYDRATE [MI]
Common Name English
ESTRASORB
Brand Name English
MYFEMBREE COMPONENT ESTRADIOL HEMIHYDRATE
Brand Name English
ESTRADIOL HEMIHYDRATE [ORANGE BOOK]
Common Name English
ESTRADIOL HEMIHYDRATE [EP MONOGRAPH]
Common Name English
ESTRADIOL HEMIHYDRATE COMPONENT OF MYFEMBREE
Brand Name English
(17.BETA.)-ESTRA-1,3,5(10)-TRIENE-3,17-DIOL HEMIHYDRATE
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS ZOELY (AUTHORIZED: CONTRACEPTION)
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
EU-Orphan Drug EU/3/05/275
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
NCI_THESAURUS C478
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
Code System Code Type Description
DRUG BANK
DBSALT001383
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
RXCUI
236859
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY RxNorm
SMS_ID
100000089218
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
PUBCHEM
154274
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
EPA CompTox
DTXSID60858948
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
FDA UNII
CXY7B3Q98Z
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
WIKIPEDIA
Estradiol hemihydrate
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
ChEMBL
CHEMBL135
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
NCI_THESAURUS
C47992
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
MERCK INDEX
m5028
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY Merck Index
DAILYMED
CXY7B3Q98Z
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
EVMPD
SUB11941MIG
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
CAS
35380-71-3
Created by admin on Fri Dec 15 15:57:13 GMT 2023 , Edited by admin on Fri Dec 15 15:57:13 GMT 2023
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (UV)
EP
ANHYDROUS->SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
For the calculation of contents, multiply the peak areas by 0.4
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY